Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.
Guggenheim downgraded Deciphera to Neutral from Buy with a $26 price target after the company entered into a definitive merger agreement with Ono Pharmaceutical for Ono to acquire Deciphera for $25.60 per share through a tender offer.